|
SCHOTT Pharma AG & Co. KGaA / Key word(s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations Based on preliminary figures, SCHOTT Pharma expects an increase in sales, EBITDA and EBITDA margin in the second quarter of 2025 (as of March 31, 2025). The company expects Q2 2025 revenues of EUR 252m, corresponding to a year-over-year growth of 10% at constant currencies. Accordingly, SCHOTT Pharma expects an EBITDA of EUR 72m and a corresponding EBITDA margin of 28.6%. These figures exceed the current market consensus of EUR 242m for revenues, 4% growth at constant currencies, EUR 62m EBITDA and a 25.5% EBITDA margin (source: Vara Research). SCHOTT Pharma maintains its full-year guidance for the fiscal year 2025 as published in December 2024. The company will publish its detailed figures for the second quarter and first half of 2025 on May 15, 2025. Investor contact Press contact End of Inside Information
10-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Germany | |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange |
| EQS News ID: | 2115610 |
| End of Announcement | EQS News Service |
|
|
2115610 10-Apr-2025 CET/CEST
If you are a journalist, please contact our Corporate Communications team.